

References

1. 1.
Noon L. Prophylactic inoculation against hay fever. *Lancet* 1911; I: 1572–3 [View Article](http://dx.doi.org/10.1016/S0140-6736(00)78276-6) ([http://dx.doi.org/10.1016/S0140-6736\(00\)78276-6](http://dx.doi.org/10.1016/S0140-6736(00)78276-6))
2. 2.
Black JH. The oral administration of pollen. *J Lab Clin Med* 1927; 12: 1156
3. 3.
Herxheimer H. Bronchial hypersensitization and hyposensitization in man. *Int Arch Allergy Appl Immunol* 1951; 40: 40–57 [View Article](http://dx.doi.org/10.1159/000227899) (<http://dx.doi.org/10.1159/000227899>)
4. 4.
Taylor G, Shivalkar PR. Local nasal desensitization in allergic rhinitis. *Clin Allergy* 1972; 2: 125–6 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=4632179) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=4632179) [View Article](http://dx.doi.org/10.1111/j.1365-2222.1972.tb01277.x) (<http://dx.doi.org/10.1111/j.1365-2222.1972.tb01277.x>)
5. 5.
Taudorf E, Weeke B. Orally administered grass pollen. *Allergy* 1983; 38: 561–4 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=6362471) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=6362471) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1983.tb04140.x) (<http://dx.doi.org/10.1111/j.1398-9995.1983.tb04140.x>)
6. 6.
Passalacqua G, Berardi M, Baena-Cagnani CE, et al. Oral and sublingual immunotherapy in pediatric patients. *Curr Opin Allergy Immunol* 2003; 3: 139–45 [View Article](http://dx.doi.org/10.1097/00130832-200304000-00008) (<http://dx.doi.org/10.1097/00130832-200304000-00008>)
7. 7.
Committee on the Safety of Medicines. CSM update: desensitizing vaccines. *BMJ* 1986; 293: 948 [View Article](http://dx.doi.org/10.1136/bmj.293.6552.948) (<http://dx.doi.org/10.1136/bmj.293.6552.948>)
8. 8.
Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. *Clin Allergy* 1986; 16: 483–91 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3536171) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3536171) [View Article](http://dx.doi.org/10.1111/j.1365-2222.1986.tb01983.x) (<http://dx.doi.org/10.1111/j.1365-2222.1986.tb01983.x>)
9. 9.
Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy and skin testing. *J Allergy Clin Immunol* 1987; 79: 660–77 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3559001) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3559001) [View Article](http://dx.doi.org/10.1016/S0091-6749(87)80164-1) ([http://dx.doi.org/10.1016/S0091-6749\(87\)80164-1](http://dx.doi.org/10.1016/S0091-6749(87)80164-1))
10. 10.
Reid MJ, Lockey RF, Turkeltaub PC, et al. Survey of fatalities from skin testing and immunotherapy. *J Allergy Clin Immunol* 1993; 92: 6–15 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8335856) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8335856) [View Article](http://dx.doi.org/10.1016/0091-6749(93)90030-J) ([http://dx.doi.org/10.1016/0091-6749\(93\)90030-J](http://dx.doi.org/10.1016/0091-6749(93)90030-J))
11. 11.
Mailing HJ, Weeke B, editors. EAACI immunotherapy position paper. *Allergy* 1993; 48 Suppl. 44: S64
12. 12.
Canonica GW, Passalacqua G. Non injection routes for immunotherapy. *J Allergy Clin Immunol* 2003; 111: 437–48 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12642818) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12642818) [View Article](http://dx.doi.org/10.1067/mai.2003.129) (<http://dx.doi.org/10.1067/mai.2003.129>)
13. 13.

- Bousquet J, Lockey R, Mailing HJ, editors. World Health Organization position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. *Allergy* 1998; 53(Suppl. 54): S3–10 [View Article](http://dx.doi.org/10.1111/j.1398-9995.1998.tb04987.x) (<http://dx.doi.org/10.1111/j.1398-9995.1998.tb04987.x>)
14. 14.
Mailing HJ, editor. EAACI position paper on local immunotherapy. *Allergy* 1998; 53: 933–44 [View Article](http://dx.doi.org/10.1111/j.1398-9995.1998.tb03793.x) (<http://dx.doi.org/10.1111/j.1398-9995.1998.tb03793.x>)
15. 15.
Bousquet J, Van Cauwenberge P, editors. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001; 108(5 Suppl.): S146–50 [View Article](http://dx.doi.org/10.1067/mai.2001.118891) (<http://dx.doi.org/10.1067/mai.2001.118891>)
16. 16.
Muller U, Mosbech H. Immunotherapy with hymenoptera venom. Position paper. *Allergy* 1993; 48 Suppl. 14: 9–35
17. 17.
Moller C, Dreborg S, Lanner A, et al. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. *Allergy* 1986; 41: 271–9 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3530030) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3530030) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1986.tb02028.x) (<http://dx.doi.org/10.1111/j.1398-9995.1986.tb02028.x>)
18. 18.
Taudorf E, Laursen CL, Lanner A, et al. Oral immunotherapy to birch pollen hay fever. *J Allergy Clin Immunol* 1987; 80: 153–61 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3301985) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3301985) [View Article](http://dx.doi.org/10.1016/0091-6749(87)90124-2) ([http://dx.doi.org/10.1016/0091-6749\(87\)90124-2](http://dx.doi.org/10.1016/0091-6749(87)90124-2))
19. 19.
Mosbech H, Dreborg S, Madsenn F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients: a one year double blind placebo controlled study. *Allergy* 1987; 42: 451–5 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3310717) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3310717) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1987.tb00362.x) (<http://dx.doi.org/10.1111/j.1398-9995.1987.tb00362.x>)
20. 20.
Mailing HJ. Immunotherapy as an effective tool in allergy treatment. *Allergy* 1998; 53: 461–72 [View Article](http://dx.doi.org/10.1111/j.1398-9995.1998.tb04082.x) (<http://dx.doi.org/10.1111/j.1398-9995.1998.tb04082.x>)
21. 21.
Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double blind study. *Allergol Immunopathol (Madr)* 1990; 18: 277–84
22. 22.
Sabbah A, Hassoun S, Le Sellin J, et al. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. *Allergy* 1994; 49: 309–13 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8092425) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8092425) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1994.tb02273.x) (<http://dx.doi.org/10.1111/j.1398-9995.1994.tb02273.x>)
23. 23.
Feliziani V, Lattuada G, Parmiani S, et al. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: a double blind study. *Allergol Immunopathol (Madr)* 1995; 23: 173–8
24. 24.
Troise C, Voltolini S, Canessa A, et al. Sublingual immunotherapy in parietaria pollen induced rhinitis: a double blind study. *J Invest Allergol Clin Immunol* 1995; 5: 25–30
25. 25.
Hirsch T, Sahn M, Leupold W. Double blind placebo controlled study of sublingual immunotherapy with house dust mite extracts in children. *Pediatr Allergy Immunol* 1997; 8: 21–7 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9260215) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9260215) [View Article](http://dx.doi.org/10.1111/j.1399-3038.1997.tb00138.x) (<http://dx.doi.org/10.1111/j.1399-3038.1997.tb00138.x>)
26. 26.
Clavel R, Bousquet J, Andre' C. Clinical efficacy of sublingual swallow immunotherapy: a double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. *Allergy* 1998; 53: 493–8 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9636808) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9636808) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1998.tb04086.x) (<http://dx.doi.org/10.1111/j.1398-9995.1998.tb04086.x>)
27. 27.
Horak F, Stubner UE, Berger U, et al. Immunotherapy with sublingual birch pollen extract: a short term double blind study. *J Invest Allergol Clin Immunol* 1998; 8: 165–71

28. 28.
Vourdas D, Syrigou E, Potamianou P, et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998; 53: 662–71PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9700035) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1998.tb03952.x) (<http://dx.doi.org/10.1111/j.1398-9995.1998.tb03952.x>)
29. 29.
Hordijk GJ, Antwelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract: a double blind placebo controlled study. Allergol Immunopathol (Madr) 1998; 26: 234–40
30. 30.
Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis. Lancet 1998; 351: 629–32PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9500318) [View Article](http://dx.doi.org/10.1016/S0140-6736(97)07055-4) ([http://dx.doi.org/10.1016/S0140-6736\(97\)07055-4](http://dx.doi.org/10.1016/S0140-6736(97)07055-4))
31. 31.
Passalacqua G, Albano M, Riccio AM, et al. Clinical and immunological effects of a rush sublingual immunotherapy to parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999; 104: 964–8PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10550740) [View Article](http://dx.doi.org/10.1016/S0091-6749(99)70076-X) ([http://dx.doi.org/10.1016/S0091-6749\(99\)70076-X](http://dx.doi.org/10.1016/S0091-6749(99)70076-X))
32. 32.
Bousquet J, Scheinmann P, Guinépain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study. Allergy 1999; 54: 249–60PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10321561) [View Article](http://dx.doi.org/10.1034/j.1398-9995.1999.00916.x) (<http://dx.doi.org/10.1034/j.1398-9995.1999.00916.x>)
33. 33.
Purello D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999; 54: 968–73PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10505460) [View Article](http://dx.doi.org/10.1034/j.1398-9995.1999.00203.x) (<http://dx.doi.org/10.1034/j.1398-9995.1999.00203.x>)
34. 34.
Pradalièr A, Basset D, Claudel A, et al. Sublingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54: 819–28PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10485385) [View Article](http://dx.doi.org/10.1034/j.1398-9995.1999.00077.x) (<http://dx.doi.org/10.1034/j.1398-9995.1999.00077.x>)
35. 35.
La Rosa M, Ranno C, André C, et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104: 425–32PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10452766) [View Article](http://dx.doi.org/10.1016/S0091-6749(99)70388-X) ([http://dx.doi.org/10.1016/S0091-6749\(99\)70388-X](http://dx.doi.org/10.1016/S0091-6749(99)70388-X))
36. 36.
Guez S, Vatrinet C, Fadel R, et al. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double blind placebo controlled study. Allergy 2000; 55: 369–75PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10782522) [View Article](http://dx.doi.org/10.1034/j.1398-9995.2000.00413.x) (<http://dx.doi.org/10.1034/j.1398-9995.2000.00413.x>)
37. 37.
Pajno GB, Morabito L, Barberio G, et al. Clinical and immunological effects of longterm sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy 2000; 55: 842–9PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11003448) [View Article](http://dx.doi.org/10.1034/j.1398-9995.2000.00495.x) (<http://dx.doi.org/10.1034/j.1398-9995.2000.00495.x>)
38. 38.
Caffarelli C, Sensi LG, Marcucci F, et al. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy. 2000; 55: 1142–7PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11117271) [View Article](http://dx.doi.org/10.1034/j.1398-9995.2000.00655.x) (<http://dx.doi.org/10.1034/j.1398-9995.2000.00655.x>)
39. 39.
Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of

40. 40.
Bahceciler NN, Isik U, Barlan IB, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32: 49–55 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11416876) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11416876) [View Article](http://dx.doi.org/10.1002/ppul.1088) (<http://dx.doi.org/10.1002/ppul.1088>)
41. 41.
Voltolini S, Modena P, Minale P, et al. Sublingual immunotherapy in tree pollen allergy: double blind, placebo controlled study with a biologically standardized extract of tree pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001; 29: 103–10
42. 42.
Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507–14 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11972594) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11972594) [View Article](http://dx.doi.org/10.1046/j.0954-7894.2002.01327.x) (<http://dx.doi.org/10.1046/j.0954-7894.2002.01327.x>)
43. 43.
Mortemousque B, Bertel F, De Casamayor J, et al. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003; 33: 464–9 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12680861) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12680861) [View Article](http://dx.doi.org/10.1046/j.1365-2222.2003.01622.x) (<http://dx.doi.org/10.1046/j.1365-2222.2003.01622.x>)
44. 44.
André C, Perrin-Fayolle M, Grosclaude M, et al. A double blind placebo controlled evaluation of SLIT with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003; 131: 111–8 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12811019) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12811019) [View Article](http://dx.doi.org/10.1159/000070926) (<http://dx.doi.org/10.1159/000070926>)
45. 45.
Ippoliti F, De Sanctis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14: 216–21 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12787302) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12787302) [View Article](http://dx.doi.org/10.1034/j.1399-3038.2003.00025.x) (<http://dx.doi.org/10.1034/j.1399-3038.2003.00025.x>)
46. 46.
Pajno G, Vita D, Caminiti D, et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003 Dec; 33(12): 1641–7 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14656349) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14656349) [View Article](http://dx.doi.org/10.1111/j.1365-2222.2003.01809.x) (<http://dx.doi.org/10.1111/j.1365-2222.2003.01809.x>)
47. 47.
Wuthrich B, Bucher CH, Jorg W, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003; 13(3): 145–8 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14635462) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14635462)
48. 48.
Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004 May; 59(5): 491–7 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15080829) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15080829) [View Article](http://dx.doi.org/10.1111/j.1398-9995.2004.00456.x) (<http://dx.doi.org/10.1111/j.1398-9995.2004.00456.x>)
49. 49.
Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59: 498–504 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15080830) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15080830) [View Article](http://dx.doi.org/10.1111/j.1398-9995.2004.00457.x) (<http://dx.doi.org/10.1111/j.1398-9995.2004.00457.x>)
50. 50.
Smith H, White P, Annila I, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114: 831–7 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15480323) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15480323) [View Article](http://dx.doi.org/10.1016/j.jaci.2004.06.058) (<http://dx.doi.org/10.1016/j.jaci.2004.06.058>)
51. 51.
Rolinck-Werninghaus C, Wolf H, Liebke C, et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the

- efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. *Allergy* 2004; 59: 1285–93 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15507097) [View Article](#) (<http://dx.doi.org/10.1111/j.1398-9995.2004.00627.x>)
52. 52.
Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. *Ann Allergy Asthma Immunol* 2004; 93: 425–30 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15562880) [View Article](#) ([http://dx.doi.org/10.1016/S1081-1206\(10\)61408-1](http://dx.doi.org/10.1016/S1081-1206(10)61408-1))
53. 53.
André C, Vatrinet C, Galvain S, et al. Safety of sublingual swallow immunotherapy in children and adults. *Int Arch Allergy Immunol* 2000; 121: 229–34 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10729782) [View Article](#) (<http://dx.doi.org/10.1159/000024322>)
54. 54.
Di Rienzo V, Pagani A, Parmiani S, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. *Allergy* 1999; 54: 1110–3 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10536891) [View Article](#) (<http://dx.doi.org/10.1034/j.1398-9995.1999.00267.x>)
55. 55.
Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. *Allergy* 2001; 56: 889–92 [View Article](#) (<http://dx.doi.org/10.1034/j.1398-9995.2001.00181.x>)
56. 56.
Pajno GB, Peroni DG, Vita D, et al. Safety of sublingual immunotherapy in children with asthma. *Paediatr Drugs* 2003; 5: 777–81 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14580226) [View Article](#) (<http://dx.doi.org/10.2165/00148581-200305110-00006>)
57. 57.
Drachenberg KJ, Urban E, Proll S, et al. Sublingual specific immunotherapy for adults and children: a post marketing survey. *Allergol Immunopathol (Madr)* 2004; 32: 76–81 [View Article](#) (<http://dx.doi.org/10.1157/13059848>)
58. 58.
Agostinis F, Tellarini L, Canonica GW, et al. Safety of SLIT in very young children. *Allergy* 2005; 60: 133 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15575951) [View Article](#) (<http://dx.doi.org/10.1111/j.1398-9995.2004.00616.x>)
59. 59.
Di Rienzo V, Musarra A, Sambugaro R, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years [abstract no. 153]. V National Congress of the Italian Society of Respiratory Medicine; 2004, Milan
60. 60.
Almagro E, Assensio O, Bartolomé JM, et al. Estudio multicentrico de farmacovigilancia de inmunoterapia sublingual en pacientes alérgicos. *Allergol Immunopathol (Madr)* 1995; 23: 153–61
61. 61.
Tinkelman DG, Cole WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. *J Allergy Clin Immunol* 1995; 95: 8–14 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7822668) [View Article](#) ([http://dx.doi.org/10.1016/S0091-6749\(95\)70146-X](http://dx.doi.org/10.1016/S0091-6749(95)70146-X))
62. 62.
Lin MS, Tanner E, Lynn J, et al. Nonfatal systemic reactions induced by skin testing and immunotherapy. *Ann Allergy* 1993; 71: 557–62 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8267250)
63. 63.
Ostergaard PA, Kaad PH, Kristensen T. A prospective study on the safety of immunotherapy in children with severe asthma. *Allergy* 1986; 41: 588–93 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3544937) [View Article](#) (<http://dx.doi.org/10.1111/j.1398-9995.1986.tb00351.x>)
64. 64.
Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. *J Allergy Clin Immunol* 1992; 90: 567–78 [PubMed](#) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1401640) [View Article](#) ([http://dx.doi.org/10.1016/0091-6749\(92\)90129-P](http://dx.doi.org/10.1016/0091-6749(92)90129-P))
65. 65.
Lockey RF, Nikoara-Kasti GL, Theodoropoulos DS, et al. Systemic reactions and fatalities associated with allergen immunotherapy.

66. 66.
Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen specific immunotherapy: a randomized placebo controlled, double blind, double dummy study. Allergy 2004; 59: 33–44 [View Article](http://dx.doi.org/10.1046/j.1398-9995.2003.00387.x) (<http://dx.doi.org/10.1046/j.1398-9995.2003.00387.x>)
67. 67.
Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251–6 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11842293) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11842293) [View Article](http://dx.doi.org/10.1067/mai.2002.121317) (<http://dx.doi.org/10.1067/mai.2002.121317>)
68. 68.
Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: VI. specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99: 450–3
69. 69.
Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study with SLIT in real life: clinical efficacy and more. Allergy 2004; 59: 944–50 [View Article](http://dx.doi.org/10.1111/j.1398-9995.2004.00508.x) (<http://dx.doi.org/10.1111/j.1398-9995.2004.00508.x>)
70. 70.
Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114: 851–7 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15480326) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15480326) [View Article](http://dx.doi.org/10.1016/j.jaci.2004.07.012) (<http://dx.doi.org/10.1016/j.jaci.2004.07.012>)
71. 71.
Passalacqua G, Bagnasco M, Mariani G, et al. Local immunotherapy: pharmacokinetics and efficacy. Allergy 1998; 53: 477–84 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9636806) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9636806) [View Article](http://dx.doi.org/10.1111/j.1398-9995.1998.tb04084.x) (<http://dx.doi.org/10.1111/j.1398-9995.1998.tb04084.x>)
72. 72.
D'Amato G, Lobefalo G, Liccardi G, et al. A double blind placebo controlled trial of local nasal immunotherapy in allergic rhinitis to parietaria pollen. Clin Exp Allergy 1995; 25: 141–8 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7750006) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7750006) [View Article](http://dx.doi.org/10.1111/j.1365-2222.1995.tb01019.x) (<http://dx.doi.org/10.1111/j.1365-2222.1995.tb01019.x>)
73. 73.
Lombardi C, Canonica GW, Passalacqua G. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy 2000; 55: 677–8 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10921471) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10921471) [View Article](http://dx.doi.org/10.1034/j.1398-9995.2000.00687.x) (<http://dx.doi.org/10.1034/j.1398-9995.2000.00687.x>)
74. 74.
Mempel M, Rakoski J, Ring J, et al. Severe anaphylaxis to kiwi fruit: immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003; 111: 1406–9 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12789247) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12789247) [View Article](http://dx.doi.org/10.1067/mai.2003.1497) (<http://dx.doi.org/10.1067/mai.2003.1497>)
75. 75.
Marcucci F, Sensi L, Frati F, et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001; 56: 1091–5 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11703225) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11703225) [View Article](http://dx.doi.org/10.1034/j.1398-9995.2001.00226.x) (<http://dx.doi.org/10.1034/j.1398-9995.2001.00226.x>)
76. 76.
Vervloet D, Birnbaum J, Laurent P, et al. Safety and clinical efficacy of rush sublingual cypress immunotherapy: preliminary results [abstract]. Allergy 2002; 57 Suppl. 73: 70
77. 77.
Grosclaude M, Bouillot P, Alt R, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. Int Arch Allergy Immunol 2002; 129: 248–53 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12444323) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12444323) [View Article](http://dx.doi.org/10.1159/000066779) (<http://dx.doi.org/10.1159/000066779>)
78. 78.
Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the mayor Parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100: 121–9 [View Article](http://dx.doi.org/10.1016/S0091-6749(97)70203-3) ([http://dx.doi.org/10.1016/S0091-6749\(97\)70203-3](http://dx.doi.org/10.1016/S0091-6749(97)70203-3))
79. 79.

- Bagnasco M, Passalacqua G, Villa G, et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. *Clin Exp Allergy* 2001; 31: 54–60 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11167951) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11167951) [View Article](http://dx.doi.org/10.1046/j.1365-2222.2001.00999.x) (<http://dx.doi.org/10.1046/j.1365-2222.2001.00999.x>)
80. 80.
Mailing HJ. Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol 2002; 2: 523–31 [View Article](http://dx.doi.org/10.1097/00130832-200212000-00008) (<http://dx.doi.org/10.1097/00130832-200212000-00008>)
81. 81.
Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane review). Cochrane Database Syst Rev 2003; (2): CD002893
82. 82.
Di Rienzo V, Marcucci F, Puccinelli P, et al. Long lasting effect of sublingual immunotherapy in children with asthma due to house dust mites: a ten-year prospective study. Clin Exp Allergy 2003; 33: 206–10 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12580913) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12580913) [View Article](http://dx.doi.org/10.1046/j.1365-2222.2003.01587.x) (<http://dx.doi.org/10.1046/j.1365-2222.2003.01587.x>)
83. 83.
Nelson HS. Advances in upper airway disease and allergen immunotherapy. J Allergy Clin Immunol 2003; 111: S793–8 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12618745) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12618745) [View Article](http://dx.doi.org/10.1067/mai.2003.150) (<http://dx.doi.org/10.1067/mai.2003.150>)
84. 84.
Douglass J, O’Hehir R. Specific allergen immunotherapy: time for alternatives? Clin Exp Allergy 2002; 32: 1–3 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12002725) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12002725) [View Article](http://dx.doi.org/10.1046/j.0022-0477.2001.01278.x) (<http://dx.doi.org/10.1046/j.0022-0477.2001.01278.x>)
85. 85.
Norman PS. Immunotherapy 1999–2004. J Allergy Clin Immunol 2004; 113: 1013–23 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15208577) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15208577) [View Article](http://dx.doi.org/10.1016/j.jaci.2004.03.020) (<http://dx.doi.org/10.1016/j.jaci.2004.03.020>)
86. 86.
Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy 2005; 60: 1–3 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15575923) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15575923) [View Article](http://dx.doi.org/10.1111/j.1398-9995.2005.00700.x) (<http://dx.doi.org/10.1111/j.1398-9995.2005.00700.x>)

About this Article

Title

Safety Profile of Sublingual Immunotherapy

Journal

Treatments in Respiratory Medicine

Volume 5, Issue 4 , pp 225-234

Cover Date

2006-08

DOI

10.2165/00151829-200605040-00001

Print ISSN

1176-3450

Publisher

Springer International Publishing

Additional Links

- [Register for Journal Updates](#)

- [Editorial Board](#)
- [About This Journal](#)
- [Manuscript Submission](#)

Topics

- [Pharmacy](#)

Authors

- [Giovanni Passalacqua](#) ⁽¹⁾
- [Laura Guerra](#) ⁽¹⁾
- [Federica Fumagalli](#) ⁽¹⁾
- [Dr Giorgio Walter Canonica](#) ⁽¹⁾

Author Affiliations

- 1. Department of Internal Medicine, Allergy & Respiratory Diseases, Padiglione Maragliano, University of Genoa, L.go R. Benzi 10, Genoa, 16132, Italy